A Morbidity-Mortality and Remodeling Study With Valsartan

Jikei University School of Medicine

Status and phase: Unknown; Phase 4

Conditions: Ischemic Heart Disease; Hypertension; Congestive Heart Failure

Treatments: Drug: valsartan

Study type: Interventional

Funder types: Other

Identifiers

NCT00133328

JHS2002

Details and patient eligibility

About

The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker (ARB), in addition to conventional treatment, will improve the prognosis of 3000 Japanese patients with cardiovascular diseases.

Full description

Several recent clinical trials have demonstrated that angiotensin II receptor blockers (ARBs) have cardiovascular as well as renal protective effects. However, it is a problem that the number of Asian patients is very little in these trials. The researchers examine the treatment meaning by ARB about the prognosis of the patient who amalgamates either among high blood pressure, the ischemic heart disease, and congestive heart failures.

Sex: All

Ages: 20 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of hypertension, ischemic heart disease and congestive heart failure

Exclusion criteria

• Pregnancy
• Severe renal damage
• Severe liver damage
• Acute myocardial infarction

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)